Illingworth Research Group are delighted to announce that senior Australian BioPharma industry executive Kevin Wightman, has joined the Illingworth team to head up Illingworth’s expansion into the rapidly growing Australian and wider Asia Pacific clinical research market.
Illingworth have been steadily growing their mobile Research Nurse and specialist Medical Photography operations in Australia and New Zealand over the last 2 years and COO Helen Springford stated “We are thrilled to welcome Kevin onboard at this exciting time in our ongoing expansion in this important region. ANZ is now recognised as a global Centre of Excellence for Clinical Research and Kevin brings more than 15 years’ invaluable experience from senior roles in some of the leading Pharma, CRO and Phase I organisations in the Australia/Asia Pacific region. He has a unique combination of operational and commercial skills and experience as well as an unparalleled network which includes many thought leaders across industry, academia and government groups”.
Having started his clinical research career with GSK in the UK Kevin moved to Melbourne with his family in 2006 and has since held positions of increasing seniority with major international CROs as well as the leading Australian Phase I unit in Melbourne. Kevin is a member of the Australian Institute of Company Directors and former member of the industry R&D Task Force. Kevin is also a an active participant in the ARCS, AusBiotech and BioMelbourne Network industry associations. He was elected by his industry peers to join the ARCS Board of Directors in 2017. Kevin has his own consultancy business and is passionate about helping international Biotech and Pharma companies to navigate the world leading Australian clinical development ecosystem.
Kevin commented “The Illingworth Research Group offers an innovative and truly patient centric approach to facilitating patient access to innovative therapies through participation in Clinical Trials. Illingworth’s experienced Research Nurses enable patients in remote communities and patients with rare or particularly severe illnesses as well as those patients with limited ability to travel to site, such as paediatric and elderly populations, to participate in clinical trials. In Australia, New Zealand and the wider AsiaPacific, this really opens up the option of clinical trial participation to many more people, both within and outside the major city locations and I am tremendously excited about the opportunity to join Illingworth as they expand their activities in this growing region.”